Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

14.86 -0.16 (-1.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Where Arcutis Biotherapeutics Stands With Analysts
 
Via Benzinga
Arcutis Biotherapeutics's Earnings Outlook
 
Via Benzinga
Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis
 
Via Benzinga
Atopic Dermatitis Player Arcutis Scoops Up DucentisBioTherapeutics
 
Via Benzinga
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
 
Via Benzinga
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics Stock Surges After Successful Atopic Dermatitis Trial
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% for mild to moderate atopic dermatitis.  
Via Benzinga
Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
Biotech stocks were hammered Wednesday, including several that had good news. 
Via Investor's Business Daily
Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
What 4 Analyst Ratings Have To Say About Arcutis Biotherapeutics
Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Upgrades 
Via Benzinga
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.